24. Jul 2026
Description
(AWP Alliance News) - BB Biotech posted a net profit of CHF 429.79 million for the first half of 2026, swinging from a loss a year earlier, with EPS at CHF 7.79. Net asset value rose 16.4% year-to-date in CHF, while the share price gained 14.1% over the same period. In the second quarter, NAV climbed 17.2% in CHF, beating the Nasdaq Biotechnology Index by 3.5 percentage points, as the group reported a net profit of CHF 451.17 million.
The discount to NAV widened to 12.9% at June 30 from 6.9% at end-March, while the portfolio ended the quarter with 37 listed holdings and 39 investments after 12 new positions. The board updated its payout policy to target a 3%-5% annual dividend yield from fiscal 2026, with the first payment due in spring 2027, and reiterated a plan to buy back up to 10% of shares over three years.
https://docs.publicnow.com/25297D3CBFA07347E789B7E5BA63EF580785EDF2
Disclaimer: This news brief was created using generative artificial intelligence. BB Biotech AG published the original content used to generate this news brief on July 24, 2026, and is solely responsible for the information contained therein.
